References
- 1. Kaakoush N, Castaño-Rodríguez N, Mitchell HM, et al. Global epidemiology of Campylobacter infection. Clin Microbiol Rev 2015; 28(3): 687–720.
- 2. EFSA, (European Food Safety Authority), ECDC (European Centre for Disease Prevention and Control), 2013. The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2011. EFSA Journal 2013; 11(4): 3129, 250 pp.
- 3. CDC, (Centers for Disease Control and Prevention). Preliminary Food Net data on the incidence of infection with pathogens transmitted commonly through food-10 states, 2009. Morb Mortal Wkly Rep 2009; 58(13): 333–7.
- 4. Zollner-Schweitz I, Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect 2015; 21: 744–749.
- 5. The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO). Diarrhoea: Why Children Are Still Dying and WhatCan Be Done, 2009.
- 6. European Centre for Disease Prevention And Control. EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and Campylobacter isolates – June 2016. Stockholm: ECDC; 2016.
- 7. Stroni GP, Dhimolea MM, Pipero PS, et al. A study of the epidemiology and etiology of acute gastroenteritis in adult patients presenting at the infectious diseases hospital in Tirana, Albania. Balkan Med J 2014; 31(3): 196–201.
- 8. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001; 32(8): 1201–1206.11283810
- 9. Man SM. The clinical importance of emerging Campylobacter species. Nat Rev Gastroenterol Hepatol 2011; 8(12): 669–685.
- 10. Walker CL, Black RE. Diarrhea morbidity and mortality in older children, adolescents and adults. Epidemiol Infect 2010; 138(9): 1215–26.
- 11. Cheng AC, McDonald JR, Thielman NM, et al. Infectious diarrhea in developed and developing countries. J Clin Gastroenterol 2005; 39(9): 757–73.10.1097/01.mcg.0000177231.13770.07
- 12. Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996; 22(6): 1019–25.10.1093/clinids/22.6.1019
- 13. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384–394.
- 14. Gaunt PN, Piddock LJV. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996; 37(4): 747–57.
- 15. Nielsen HL, Ejlertsen T, Engberg J, et al. High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: a population-based study. Clin Microbiol Infect 2013; 19(5): 445–50.10.1111/j.1469-0691.2012.03852.x
- 16. Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006; 8(7): 1955–1966.10.1016/j.micinf.2005.12.030
- 17. Emonet S, Redzepi B, Riat A, et al. Colitis due to Campylobacter jejuni/coli. Ceftriaxone is not effective. J Gerontol Geriatr Res 2017; 6: 426.
- 18. EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2017. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2015. EFSA Journal 2017; 15(2): 4694, 212 pp.
- 19. Hakanen A, Jousimies-Somer H, Siitonen A, et al. Fluoroquinolone resistance in Campylobacter jejuni isolates in travellers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003; 9(2): 267–270.10.3201/eid0902.020227
- 20. Vlieghe ER, Jacobs JA, Van Esbroeck M, et al. Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travellers, 1994 to 2006. J Travel Med 2008; 15(6): 419–25.